Global Recombinant DNA technology Market || KEYPLAYERS Pfizer, Inc., F.Hoffmann-La Roche Ltd, Cibus, Ltd

Growing technological advancement in the genetic engineering field to deliver highly efficient therapeutics for life threatening human diseases and in agriculture field is major driving factor for growth of the global recombinant DNA technology market. In addition, huge expansion of biopharmaceutical industry, coupled with rising research initiatives in this field are major factors expected to foster the target market growth. Also, increasing strategic collaborations among the major players operating in this market is a factor expected to propel growth of the global recombinant DNA technology market over the forecast period. However, high cost and adverse effects associated with the gene therapies such as neurological toxicities are key factors to hampering growth of the global recombinant DNA technology market.

Global recombinant DNA technology market is segmented on the basis of product type, component type, application type, end-user, and region. On the basis of product type, the global recombinant DNA technology market is categorized into medical and non-medical. Further, medical sub-segment is segmented into human protein, therapeutic agent, and vaccines. Non-medical sub-segment is classified into specialty chemical, biotech crops, and others. On the basis of component type, the target market has been bifurcated into expression system, and cloning vector. Expression system sub-segment is categorized into mammalian, bacteria, yeast, baculovirus/insect, and others.

On the basis of application type, the target market is segmented into agriculture and pharmaceuticals. Pharmaceuticals are categorized into human, animal, environment and others. On the basis of end-user, the recombinant DNA technology market is segmented into pharmaceutical companies, research institutes, and others.

On the basis of region, the global recombinant DNA technology market has been segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. The market in North America is expected to account for major revenue share in the global market as compared to that of other regions. This can be attributed to presence of effective regulations and guidelines for the approval of recombinant products also government support for research and developments in biotechnological companies in the countries of the region. sAlso, the market in Europe is expected to account for second-highest revenue share in the global market, followed by the market in Asia Pacific.

Key players operating in the global recombinant DNA technology market includes Pfizer, Inc., F.Hoffmann-La Roche Ltd, Cibus, Ltd., New England Biolabs,Inc., Trofacgen,Inc., GenScript, Corporation, GlaxoSmithKline plc., Novo Nordisk AS, Monsanto Company, Eli Lily and Company, Horizon Discovery Group PLC, Amgen Inc., and Novartis AG.

Contact Us:
Mr Alex (Sales Manager)
Prophecy Market Insights
Phone: +91 777 504 9802
+1 860 531 2701
Email: sales@prophecymarketinsights.com

About us:
Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business.

This release was published on openPR.